Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure.
作者信息
Jaiswal Sarita Rani, Malhotra Pankaj, Mitra Dipendra K, Chakrabarti Suparno
机构信息
Cellular Therapy and Immunology, Manashi Chakrabarti Foundation.
Department of Blood and Marrow Transplantation Dharamshila Narayana Super-speciality Hospital, New Delhi, India.
出版信息
Mediterr J Hematol Infect Dis. 2020 Jul 1;12(1):e2020047. doi: 10.4084/MJHID.2020.047. eCollection 2020.
Abstract
摘要
相似文献
1
Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure.聚焦于自然杀伤细胞中独特的先天记忆细胞群体以对抗新冠病毒：利用巨细胞病毒感染的普遍性
Mediterr J Hematol Infect Dis. 2020 Jul 1;12(1):e2020047. doi: 10.4084/MJHID.2020.047. eCollection 2020.
2
Cytomegalovirus: an unlikely ally in the fight against blood cancers?巨细胞病毒：对抗血液癌症的不寻常盟友？
Clin Exp Immunol. 2018 Sep;193(3):265-274. doi: 10.1111/cei.13152.
3
Chronic HIV-1 viremia reverses NKG2A/NKG2C ratio on natural killer cells in patients with human cytomegalovirus co-infection.慢性 HIV-1 病毒血症逆转了人巨细胞病毒合并感染患者自然杀伤细胞上的 NKG2A/NKG2C 比值。
AIDS. 2010 Jan 2;24(1):27-34. doi: 10.1097/QAD.0b013e3283328d1f.
4
Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function.同种异体移植后巨细胞病毒再激活可促进具有强大功能的成熟 NKG2C+自然杀伤细胞的持久增加。
Blood. 2012 Mar 15;119(11):2665-74. doi: 10.1182/blood-2011-10-386995. Epub 2011 Dec 16.
5
Expansion of a unique CD57⁺NKG2Chi natural killer cell subset during acute human cytomegalovirus infection.急性人巨细胞病毒感染期间独特的 CD57⁺NKG2Chi 自然杀伤细胞亚群的扩增。
Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14725-32. doi: 10.1073/pnas.1110900108. Epub 2011 Aug 8.
6
Cytomegalovirus-Driven Adaption of Natural Killer Cells in NKG2C Human Immunodeficiency Virus-Infected Individuals.巨细胞病毒驱动的自然杀伤细胞适应在 NKG2C 人类免疫缺陷病毒感染个体中。
Viruses. 2019 Mar 9;11(3):239. doi: 10.3390/v11030239.
7
Expansion of the NKG2C+ natural killer-cell subset is associated with high-risk carotid atherosclerotic plaques in seropositive patients for human cytomegalovirus.NKG2C+ 自然杀伤细胞亚群的扩增与人类巨细胞病毒血清阳性患者的高危颈动脉粥样硬化斑块相关。
Arterioscler Thromb Vasc Biol. 2013 Nov;33(11):2653-9. doi: 10.1161/ATVBAHA.113.302163. Epub 2013 Aug 22.
8
NK cells from COVID-19 positive patients exhibit enhanced cytotoxic activity upon NKG2A and KIR2DL1 blockade.来自 COVID-19 阳性患者的 NK 细胞在阻断 NKG2A 和 KIR2DL1 后表现出增强的细胞毒性活性。
Front Immunol. 2023 Jul 7;14:1022890. doi: 10.3389/fimmu.2023.1022890. eCollection 2023.
9
Impact of an Immune Modulator Mycobacterium-w on Adaptive Natural Killer Cells and Protection Against COVID-19.免疫调节剂分枝杆菌对适应性自然杀伤细胞的影响及其对 COVID-19 的保护作用。
Front Immunol. 2022 May 4;13:887230. doi: 10.3389/fimmu.2022.887230. eCollection 2022.
10
Siglec-9 Restrains Antibody-Dependent Natural Killer Cell Cytotoxicity against SARS-CoV-2.Siglec-9 抑制针对 SARS-CoV-2 的抗体依赖的自然杀伤细胞细胞毒性。
mBio. 2023 Feb 28;14(1):e0339322. doi: 10.1128/mbio.03393-22. Epub 2023 Feb 2.
引用本文的文献
1
NK Cells: A Powerful Squad Versus SARS-CoV-2.自然杀伤细胞：对抗新冠病毒的强大力量
Int J Mol Sci. 2025 Jul 6;26(13):6500. doi: 10.3390/ijms26136500.
2
Mitochondria in COVID-19: from cellular and molecular perspective.新型冠状病毒肺炎中的线粒体：从细胞和分子角度看
Front Physiol. 2024 Jun 21;15:1406635. doi: 10.3389/fphys.2024.1406635. eCollection 2024.
3
Natural killer cells and their exosomes in viral infections and related therapeutic approaches: where are we?自然杀伤细胞及其细胞外囊泡在病毒感染及相关治疗方法中的作用：我们的研究进展如何？
Cell Commun Signal. 2023 Sep 25;21(1):261. doi: 10.1186/s12964-023-01266-2.
4
Natural killer cells in COVID-19: from infection, to vaccination and therapy.新冠病毒疾病中的自然杀伤细胞：从感染到疫苗接种及治疗
Future Virol. 2023 Feb. doi: 10.2217/fvl-2022-0040. Epub 2023 Mar 14.
5
NK cell dysfunction is linked with disease severity in SARS-CoV-2 patients.自然杀伤细胞功能障碍与 SARS-CoV-2 患者的疾病严重程度有关。
Cell Biochem Funct. 2022 Aug;40(6):559-568. doi: 10.1002/cbf.3725. Epub 2022 Jul 14.
6
Impact of an Immune Modulator Mycobacterium-w on Adaptive Natural Killer Cells and Protection Against COVID-19.免疫调节剂分枝杆菌对适应性自然杀伤细胞的影响及其对 COVID-19 的保护作用。
Front Immunol. 2022 May 4;13:887230. doi: 10.3389/fimmu.2022.887230. eCollection 2022.
7
The impact of lymphoid memory cells in different ages of COVID-19 patients.淋巴细胞记忆细胞在不同年龄新冠患者中的影响。
Gene Rep. 2022 Mar;26:101503. doi: 10.1016/j.genrep.2022.101503. Epub 2022 Jan 15.
8
Impact of adaptive natural killer cells, KLRC2 genotype and cytomegalovirus reactivation on late mortality in patients with severe COVID-19 lung disease.适应性自然杀伤细胞、KLRC2基因分型和巨细胞病毒再激活对重症COVID-19肺病患者晚期死亡率的影响
Clin Transl Immunology. 2022 Jan 11;11(1):e1359. doi: 10.1002/cti2.1359. eCollection 2022.
9
Cytomegalovirus-Induced Gastrointestinal Bleeding and Pancreatitis Complicating Severe Covid-19 Pneumonia: A Paradigmatic Case.巨细胞病毒诱导的胃肠道出血和胰腺炎并发重症新冠病毒肺炎：一个典型病例
Mediterr J Hematol Infect Dis. 2020 Sep 1;12(1):e2020060. doi: 10.4084/MJHID.2020.060. eCollection 2020.
10
Aryl Hydrocarbon Receptor Role in Co-Ordinating SARS-CoV-2 Entry and Symptomatology: Linking Cytotoxicity Changes in COVID-19 and Cancers; Modulation by Racial Discrimination Stress.芳烃受体在协调严重急性呼吸综合征冠状病毒2（SARS-CoV-2）进入和症状学中的作用：连接2019冠状病毒病（COVID-19）和癌症中的细胞毒性变化；种族歧视应激的调节作用
Biology (Basel). 2020 Aug 27;9(9):249. doi: 10.3390/biology9090249.
本文引用的文献
1
Prophylactic oseltamivir during major seasonal influenza H1N1 outbreak might reduce both H1N1 and associated pulmonary aspergillosis in children undergoing haploidentical transplantation.在季节性大流行的 H1N1 流感期间，预防性使用奥司他韦可能会降低接受单倍体相合移植的儿童中 H1N1 流感和相关的肺曲霉病的发生率。
Transpl Infect Dis. 2020 Oct;22(5):e13309. doi: 10.1111/tid.13309. Epub 2020 Jun 8.
2
NKG2A and COVID-19: another brick in the wall.自然杀伤细胞2A（NKG2A）与新型冠状病毒肺炎（COVID-19）：拼图中的另一块拼图。
Cell Mol Immunol. 2020 Jun;17(6):672-674. doi: 10.1038/s41423-020-0450-7. Epub 2020 May 7.
3
Safety of an immunomodulator w in COVID-19.一种免疫调节剂在新冠病毒肺炎中的安全性。
Lung India. 2020 May-Jun;37(3):279-281. doi: 10.4103/lungindia.lungindia_242_20.
4
Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents.由NKG2A受体介导的COVID-19患者的先天免疫，以及使用莫那利珠单抗、氯喹和抗病毒药物的潜在治疗方法。
Med Hypotheses. 2020 Apr 22;140:109777. doi: 10.1016/j.mehy.2020.109777.
5
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.严重 COVID-19 中的细胞因子释放综合征：白细胞介素-6 受体拮抗剂托珠单抗可能是降低死亡率的关键。
Int J Antimicrob Agents. 2020 May;55(5):105954. doi: 10.1016/j.ijantimicag.2020.105954. Epub 2020 Mar 29.
6
Clinical and immunological features of severe and moderate coronavirus disease 2019.新型冠状病毒病 2019 重症和中度患者的临床和免疫学特征。
J Clin Invest. 2020 May 1;130(5):2620-2629. doi: 10.1172/JCI137244.
7
Functional exhaustion of antiviral lymphocytes in COVID-19 patients.新冠病毒肺炎患者抗病毒淋巴细胞的功能耗竭
Cell Mol Immunol. 2020 May;17(5):533-535. doi: 10.1038/s41423-020-0402-2. Epub 2020 Mar 19.
8
Characteristics of COVID-19 infection in Beijing.北京地区 COVID-19 感染特征。
J Infect. 2020 Apr;80(4):401-406. doi: 10.1016/j.jinf.2020.02.018. Epub 2020 Feb 27.
9
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
10
A Novel Coronavirus from Patients with Pneumonia in China, 2019.2019 年中国肺炎患者中的一种新型冠状病毒。
N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.
Zotero 插件